On this page
- What stem cells actually are
- Where the cells come from
- What the evidence supports, by condition
- Why it is available here and not at home
- How the cells are prepared in published work
- How it is given
- Safety, described honestly
- What it costs, and why nobody can quote you a price
- Who may be worth assessing, and who is not
- Questions worth asking any clinic
- Where to read further on this site
- Frequently asked questions
- Requesting a medical evaluation
People come to Thailand for regenerative treatment because it is available here and restricted at home. That is a real difference, and it is worth understanding why it exists before booking anything. Stem cell therapy in Thailand covers a wide span — from applications with randomised trials and meta-analyses behind them, to applications with almost nothing but laboratory work and hope.
What stem cells actually are
A stem cell is a cell that has not yet committed to being one particular kind of tissue, and which can divide to produce more of itself. That is the whole definition. Everything else — what it might do in a joint, in a bloodstream, in a damaged spinal cord — is a separate question with a separate answer for each case.
The distinction that matters commercially is between haematopoietic stem cells, which rebuild blood and immune systems and have been used in hospital transplant medicine for decades, and mesenchymal stromal cells, usually written MSCs, which are what almost every clinic offering “stem cell therapy” is actually selling.
These are not interchangeable, and the evidence for one does not carry across to the other. That single confusion does more work in stem cell marketing than any other, which is why it has a page of its own here — see HSCT versus MSC infusion.
Where the cells come from
Autologous cells are your own, taken from your fat or bone marrow during a procedure that is itself not trivial. Allogeneic cells come from a donor, most often from umbilical cord tissue donated after a normal birth.
Each has trade-offs that published trials treat seriously. Autologous cells avoid donor matching questions but vary enormously in number and quality with the patient’s age and health. Allogeneic cord-derived cells are more uniform and available immediately, and raise questions about donor screening and immune response instead.
A 2024 network meta-analysis compared cell types directly in knee osteoarthritis and found differences between them — Transplantation of three mesenchymal stem cells for knee osteoarthritis — which is a useful reminder that “stem cell therapy” describes a category, not a product.
What the evidence supports, by condition
The honest summary is that evidence quality falls away sharply as you move from joints to organs to the nervous system.
- Knee osteoarthritis — the strongest case. Multiple randomised trials and meta-analyses. See knee osteoarthritis.
- Other joints and cartilage — plausible by extension, much less directly studied.
- Diabetic foot ulcers — randomised evidence exists in a narrow indication.
- Autoimmune and rheumatic disease — early human evidence, heterogeneous.
- Stroke, spinal cord injury, neurological disease — studied, not established.
- Anti-ageing, autism, general wellness — no reliable human evidence at all.
Any clinic willing to treat everything on that list with the same infusion is telling you something about how it decides what to offer.
Why it is available here and not at home
In the United States, most cell preparations that are more than minimally manipulated are regulated as drugs, and a drug requires approval from trials before it can be sold. That is why a treatment you can pay for in Bangkok is unavailable in Boston.
It is worth being clear about what that difference is and is not. It is not evidence that the treatment works and American patients are missing out. It is a difference in how much proof a regulator demands before a thing may be sold.
Thailand has its own regulatory framework and it is not absent — see stem cell regulation in Thailand and the Thailand and United States comparison.
How the cells are prepared in published work
This describes what the literature reports. It is not a description of any particular clinic’s process, and you should ask any clinic you are considering to describe its own.
Tissue is collected, cells are isolated and then expanded in culture over roughly two to four weeks until there are enough for a dose. They are characterised against surface-marker criteria, tested for sterility and for viability, and either used fresh or cryopreserved.
Dose in trials is usually expressed as cells per kilogram or as a fixed count per joint, and it varies by more than an order of magnitude between studies — which is one reason results are hard to compare. See MSC dosage research.
How it is given
Intra-articular injection puts cells directly into a joint and is what the osteoarthritis trials almost all used. Intravenous infusion distributes cells systemically and is what most non-orthopaedic applications use.
The two routes are studied for different things and have different risk profiles. An injection into a knee carries the ordinary risks of a joint injection. An infusion into a vein carries different ones.
Intrathecal and intralesional routes appear in neurological research. They are more invasive again, and their use outside a trial is a decision that deserves a great deal of scrutiny.
Safety, described honestly
Across trials, MSC administration has generally been reported as well tolerated in the short term, with the commonest events being transient — pain and swelling at an injection site, brief fever after an infusion.
That statement carries two limits worth stating alongside it. Trial populations are selected, and trial follow-up is mostly measured in months rather than decades. Long-term safety data is thin simply because the treatments are not old.
Harms in the unregulated sector are a separate matter and are documented — see stem cell adverse events and safety studies.
What it costs, and why nobody can quote you a price
Cost depends on the cell type, the number of cells, how many treatments are given, whether the cells are your own, what imaging and laboratory work is needed first, and whether any of it requires a hospital rather than a clinic.
A single headline figure for “stem cell treatment” is close to meaningless across that range, and a very low one usually means something specific about the dose or the preparation.
The variables are set out in full on the cost page, including what to ask so that two quotes can actually be compared.
Who may be worth assessing, and who is not
Broadly, the people for whom there is most to discuss have a condition with some published human evidence, have already tried established treatment, and have realistic expectations about what a trial-sized effect feels like.
Active malignancy, active infection, pregnancy and significant organ failure appear as exclusions across the trial literature, and a clinic that does not ask about them is not assessing you.
Nobody can tell you from a web page whether you are suitable. That needs your history and your imaging read by a clinician — see the patient journey.
Questions worth asking any clinic
Ask them of us, and ask them of everyone else you are considering. A clinic that answers them plainly is telling you something; so is one that does not.
- What cell type, from what source, and is it autologous or allogeneic?
- How many cells, and how was that number chosen?
- Where are the cells processed, and what release testing is done?
- What published evidence exists for this cell type, in this condition, by this route?
- What happens if I am assessed and found unsuitable — is any of the fee refundable?
- What follow-up happens after I fly home?
See the international patients page for how records review works before you travel.
Where to read further on this site
The research library holds the evidence summaries every clinical page here draws on, with the trials named and linked.
Mesenchymal stem cell therapy covers the cell type most of this concerns. Exosome therapy covers something sold alongside it that is not stem cell therapy at all.
What the evidence levels mean explains the labels used at the top of every clinical page here.
Autoimmune conditions and ischaemic heart disease are the two areas with the largest bodies of randomised evidence, and both are covered in full.
The conditions index lists every condition covered here with its evidence grade, and the treatments index sets out how the products differ from one another.
Frequently asked questions
Is stem cell therapy legal in Thailand?
Thailand regulates cell therapy, and the framework is not absent. What is permitted, and under what conditions, is set out on the regulation page with official sources.
Why can I get this in Thailand but not at home?
Most regulators treat expanded cell preparations as drugs needing approval from trials. That is a difference in required proof, not evidence that the treatment works.
How much does it cost?
It depends on cell type, dose, number of treatments and what work is needed first. A single figure across that range would be misleading, so the cost page sets out the variables instead.
What has the best evidence behind it?
Knee osteoarthritis, by some distance — several randomised trials and more than one meta-analysis. Evidence thins quickly for other indications.
Is it safe?
Short-term tolerability in trials has generally been good. Follow-up is mostly months rather than years, so long-term data is genuinely limited.
Will it help my condition?
Nobody can answer that from a website. It needs your history and imaging reviewed, and for several conditions the honest answer after that review is no.
How long would I need to stay in Thailand?
That depends on whether cells are autologous, since harvesting and expansion take weeks. The international patients page covers the timelines.
What if I am assessed as unsuitable?
Then you should be told so. Ask before paying anything what happens in that case — it is one of the more revealing questions you can ask a clinic.
Requesting a medical evaluation
Nothing on this page establishes whether any treatment is appropriate for you. That needs your history, your imaging and your current medications read by a clinician. If you would like that review, send your records and we will tell you honestly whether there is anything worth discussing — including when the answer is no.
This page is general information, not medical advice, and does not create a doctor–patient relationship. Regenerative treatments discussed here are in most cases investigational. Discuss any treatment with a clinician who knows your history.